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Background: Dopamine agonists (DAs) are a first-line therapy for moderate-to-severe restless legs syndrome (RLS),
but these treatments may lead to complications, such as augmentation and impulse control disorders, requiring
switching to another therapeutic class. Here we assess efficacy and tolerability of gabapentin enacarbil (GEn) in
adults with moderate-to-severe primary RLS, with or without prior DA exposure.
Methods: Data from 3 trials were pooled. Patients were identified as DA-naive or DA-exposed, based on prior treatment
with ropinirole, pramipexole, rotigotine, or pergolide mesylate, and the dopamine precursor levodopa. Details on prior
treatment duration and dose were unavailable. Patients with a history of augmentation were excluded. Within DA-naive/
DA-exposed patients we investigated the co-primary end points from the pivotal trials: mean change from baseline to
week 12 in International RLS (IRLS) Rating Scale total score and proportion of responders (“much”/“very much” improved)
on the investigator-rated Clinical Global Impression–Improvement (CGI-I) scale. Safety was also assessed.
Results: 671 patients were randomized (DA-naive: placebo, n = 194; GEn 600 mg, n = 131; GEn 1200 mg, n = 214;
DA-exposed: placebo, n = 50; GEn 600 mg, n = 30; GEn 1200 mg, n = 52). Across treatment arms, no significant
differences between DA-naive and DA-exposed subgroups in IRLS Rating Scale total score change from baseline at
any visit were seen, except week 1 in the placebo group (−6.1 DA-naive vs −3.4 DA-exposed, P = .020). No significant
differences in the odds of CGI-I response at week 12 between DA-naive vs DA-exposed patients in any treatment group
were seen; however, with placebo there was a nonsignificant trend toward fewer responders among DA-exposed
(34.0%) vs DA-naive (44.3%) patients. Both GEn doses significantly improved the IRLS Rating Scale total score change
from baseline and CGI-I response vs placebo, regardless of prior DA exposure. The most common treatment-emergent
adverse events were dizziness and somnolence.
Conclusions: Prior DA exposure had no significant effect on efficacy or tolerability of GEn (600 or 1200 mg) in this
pooled analysis of adults with moderate-to-severe primary RLS. These data support the use of GEn in DA-exposed and
DA-naive patients.
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Restless legs syndrome (RLS), also known as Willis-Ekbom
disease, is a common neurological disorder characterized
by an urge to move the legs. This urge is frequently accom-
panied by unpleasant sensations in the legs, worsens in the
evening and at rest, and is transiently improved with activ-
ity [1,2]. Patients with RLS experience significant impair-
ments in sleep, daytime or social functioning, and overall
quality of life [3,4].
Over the past decade, dopamine agonists (DAs) have
been used as first-line therapy for patients with moderate-
to-severe primary RLS [5]. Three DAs—ropinirole, prami-
pexole, and rotigotine—have been approved by the US
Food and Drug Administration (FDA) for the treatment
of moderate-to-severe primary RLS [2]. Though initially
effective, the benefit of treatment with DAs may lessen
over time owing to a variety of factors which may
include augmentation, tolerance, or dopaminergic down-
regulation. In particular, augmentation leads to a paradox-
ical scenario involving a worsening and earlier phase shift
of RLS symptoms during treatment [6,7]. Some RLS
patients who are treated with DAs may also develop im-
pulse control disorders [2,8]. These developments may
warrant switching to an alternate class of drugs when
these side effects develop.
Gabapentin enacarbil (GEn), an agent in the alpha-
2-delta ligand class of drugs, is an actively transported
prodrug of gabapentin. GEn is approved by the FDA at
a dose of 600 mg once daily for the treatment of
moderate-to-severe primary RLS in adults. GEn is also
approved for the management of postherpetic neuralgia
in adults (600 mg twice daily) [9] and remains the only
FDA-approved non-DA alternative for the treatment of
moderate-to-severe primary RLS. In 3 randomized,
double-blind, placebo-controlled studies in adult pa-
tients with moderate-to-severe primary RLS (XP052/
XP053/XP081), GEn (600 mg and 1200 mg) significantly
improved RLS symptoms compared with placebo, as
assessed by the mean change from baseline in Inter-
national RLS (IRLS) Rating Scale total score and the
proportion of responders on the investigator-rated Clin-
ical Global Impression–Improvement (CGI-I) scale at
week 12. In all 3 studies, the most commonly reported
adverse events were somnolence and dizziness [10-12].
When physicians consider how to treat patients with
RLS, the potential effect of prior DA exposure on the
efficacy of the new agent could be a factor. The effect of
starting alternative agents, such as GEn, following
exposure to DAs has not yet been examined. To investi-
gate the effect of prior DA exposure on response to
GEn treatment in adult patients with moderate-to-
severe primary RLS, we compared outcomes for pa-
tients with and without prior DA exposure using pooled
data from the XP052, XP053, and XP081 studies.Methods
Study design and patients
The study designs and patient populations of the 3 pri-
mary studies (XP052, XP053, and XP081) have been
published previously (ClinicalTrials.gov NCT00298623,
NCT00365352, and NCT01332305) [10-12]. These were
phase 2 or 3, double-blind, 12-week, placebo-controlled
trials in adults with moderate-to-severe primary RLS, as
defined by the IRLS Study Group diagnostic criteria [13].
For this analysis, data were pooled for each treat-
ment from the XP052 (GEn 1200 mg and placebo)
and XP053 (GEn 600 mg, GEn 1200 mg, and placebo)
studies. Patients were grouped based on previous DA
treatment status. Considering that augmentation was
an exclusion criterion from study participation, the rate
of any preceding augmentation was not rigorously
assessed and thus remains unknown. In addition, the
extent of treatment duration and dose of prior DA
therapy were also not available. All subjects provided
written informed consent prior to study participation.
The primary studies were conducted in accordance with
good clinical practice guidelines and the Declaration of
Helsinki.
Co-primary end points from the pivotal trials, and in-
vestigated in the present analysis, were mean change in
IRLS Rating Scale total score from baseline to week 12
[14], and the proportion of responders (“much” or “very
much” improved) on the investigator-rated CGI-I scale
[15] at week 12 for GEn 600 mg and GEn 1200 mg com-
pared with placebo. Safety outcomes included treatment-
emergent adverse events (TEAEs) and serious AEs.
Statistical analyses
Efficacy analyses were performed on the modified
intent-to-treat population (all patients in the safety
population with a baseline and ≥1 post-baseline IRLS
Rating Scale total score). Missing data were imputed
using the last observation carried forward for analyses
of the investigator-rated CGI-I data, and a mixed-
effect model for repeated measures (MMRM) with
observed cases (no imputation) was used for analysis of
the IRLS Rating Scale total score. The main compari-
sons for all efficacy analyses were within treatments
across DA status (by visit for IRLS Rating Scale total
score).
For the change from baseline IRLS Rating Scale total
scores, the effects of prior DA exposure were analyzed
using MMRM with an unstructured covariance matrix,
including fixed effects for treatment, visit, treatment-
by-visit interaction, baseline IRLS Rating Scale total
score, DA history (yes/no), DA history-by-treatment
interaction, DA history-by-visit interaction, and DA
history-by-treatment-by-visit interaction. For the per-
centage of CGI-I responders, the effect of prior DA
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model with the following factors: treatment, DA history
(yes/no), and DA history-by-treatment interaction.
Results
Patients
In this pooled analysis, 19.7% (132/671) of patients had
been previously exposed to DAs. Ropinirole was the most
frequently reported prior DA across the 3 treatment arms
(Table 1). In general, a greater proportion of DA-exposed
patients had severe RLS at baseline compared with DA-
naive patients (IRLS Rating Scale total score ≥24; 59.9% vs
42.7%). In the DA-naive group, 16.7% (90/539) of patients
received non-DA prior treatment for RLS. Although not
FDA-approved for the treatment of primary moderate-to-
severe primary RLS, these non-DA prior treatments in-
cluded gabapentin, non-steroidal anti-inflammatory drugs,
sleep aids, clonazapam, tramadol, cyclobenzaprine, and
quinine (Table 1). The mean duration of RLS symptomsTable 1 Baseline characteristics of DA-naive and DA-exposed




Age at screening, mean years (SD) 48.9 (12.78) 47.2
Sex, n (%)
Female 122 (63) 75 (5
Male 72 (37) 56 (4
Race, n (%)
White/Caucasian 186 (96) 123 (
Mean baseline IRLS Rating Scale total score, points (SD) 22.5 (4.76) 23.2
Mean IRLS Rating Scale total score, n (%)
<24 at baseline 116 (60) 67 (5
≥24 at baseline 78 (40) 64 (4
Duration of RLS symptoms, years
Mean (SD) 13.1 (12.29) 12.5
Prior RLS treatment, n (%)
Yesa 39 (20)c 20 (1





Pergolide mesylate N/A N/A
Levodopab N/A N/A
aIncludes patients whose treatment terminated prior to the month before the start
of study drug or within the previous month. bClassified as dopaminergic agents. Pa
were included in the DA-exposed group. cExamples of non-DA prior treatment include
HCL, clonazepam, diazepam, trazodone, tramadol, propoxyphene, cyclobenzaprine, an
primary moderate-to-severe RLS and list is not inclusive of all prior treatments reported
DA, dopamine agonist; GEn, gabapentin enacarbil; IRLS, International Restless Legs
syndrome; SD, standard deviation.was 12.5 to 13.9 years in the DA-naive group and 16.1
to 17.9 years in the DA-exposed group. Of the DA-
naive patients, 82.0% (159/194) in the placebo group,
84.7% (111/131) in the GEn 600-mg group, and 86.0%
(184/214) in the GEn 1200-mg group completed their
respective study. Among the DA-exposed patients,
82.0% (41/50) in the placebo group, 90.0% (27/30) in
the GEn 600-mg group, and 86.5% (45/52) in the GEn
1200-mg group completed their respective study (Table 1).
End points
At week 12, prior DA exposure had no effect on the
change in IRLS Rating Scale total score from baseline in
the placebo (treatment difference between DA-naive and
DA-exposed patients: −0.6 [1.3], P = .673), GEn 600-mg
(treatment difference: −0.5 [1.6], P = .762), or GEn 1200-mg
(treatment difference: 0.1 [1.3], P = .964) groups (Figure 1).
With the exception of week 1 in the placebo group,
there were no statistically significant differences inpatients (mITT population)
) DA-exposed (n = 132)








(12.85) 49.8 (11.99) 50.5 (10.33) 52.4 (11.26) 54.2 (14.40)
7) 122 (57) 29 (58) 21 (70) 31 (60)
3) 92 (43) 21 (42) 9 (30) 21 (40)
94) 206 (96) 48 (96) 29 (97) 50 (96)
(4.98) 22.9 (5.07) 25.2 (4.72) 24.0 (5.34) 24.6 (5.28)
1) 126 (59) 18 (36) 14 (47) 21 (40)
9) 88 (41) 32 (64) 16 (53) 31 (60)
(12.82) 13.9 (13.33) 17.0 (15.13) 17.9 (12.09) 16.1 (16.80)
5)c 31 (14)c 50 (100) 30 (100) 52 (100)
N/A 39 (78) 26 (87) 38 (73)
N/A 9 (18) 5 (17) 10 (19)
N/A 7 (14) 2 (7) 4 (8)
N/A 2 (4) 2 (7) 2 (4)
N/A 1 (2) 0 0
N/A 0 0 1 (2)
of study drug, and those who received treatment within the month of the start
tients with a past history of treatment with levodopa-carbidopa and levodopa
: gabapentin, non-steroidal anti-inflammatory drugs, zolpidem, diphenhydramine
d quinine. Please note, these treatments are not FDA approved treatments for
.






































Values were derived from the mixed-effect model for repeated measures.
Figure 1 IRLS Rating Scale total score change from baseline in DA-naive vs DA-exposed patients (week 12). Change from baseline
reported as the LS mean change from baseline. DA, dopamine agonist; Diff, mean treatment difference between DA-naive and DA-exposed
treatment groups; GEn, gabapentin enacarbil; IRLS, International Restless Legs Syndrome; LS, least squares; SE, standard error.
Ondo et al. Journal of Clinical Movement Disorders  (2015) 2:9 Page 4 of 7change in IRLS Rating Scale total score from baseline
between the DA-naive vs DA-exposed patients in any
treatment arm at any of the visits (Figure 2). At week 1, the
change from baseline in the IRLS Rating Scale was greater
in the DA-naive patients compared with the DA-exposed
patients treated with placebo (−6.1 vs −3.4, P = .020).
There were also no significant differences in the odds
of being a CGI-I responder between the DA-naive vs
DA-exposed patients in any of the treatment groups at
week 12 (Figure 3), although the DA-exposed placebo
group showed a nonsignificant trend toward fewer re-
sponders compared with the DA-naive placebo group
(34.0% vs 44.3%, respectively).
Regardless of whether they had prior DA exposure,
patients showed significant improvements in IRLS Rat-
ing Scale total score change from baseline with both
GEn doses compared with placebo at most time points
(Figure 2). Significantly more patients receiving GEn
(600 mg or 1200 mg) were CGI-I responders compared
with patients receiving placebo in both DA-naive and
DA-exposed groups (Figure 3).
Tolerability
The TEAE profile was similar between DA-exposed and
DA-naive patients. The most commonly reported TEAEs
in the safety population were somnolence and dizziness
(Table 2). Thirty-eight patients (7%) in the DA-naive
group (GEn 600 mg, n = 10; GEn 1200 mg, n = 18; pla-
cebo, n = 10) and 6 patients (5%) in the DA-exposed
group (GEn 600 mg, n = 1; GEn 1200 mg, n = 5; placebo,
n = 0) discontinued treatment because of an AE. The
majority of AEs were rated as mild or moderate in inten-
sity. A total of 6 patients reported serious AEs: cellulitis
(DA-naive, GEn 600 mg), worsened peripheral arterial
disease (DA-naive, placebo), worsening cholelithiasis
(DA-naive, GEn 1200 mg), cholelithiasis (DA-exposed, pla-
cebo), appendicitis (DA-exposed, placebo), and herniateddisc (DA-exposed, GEn 600 mg). None of these events
were considered treatment-related, and 5 of the 6 pa-
tients recovered (the outcome of 1 patient with wors-
ened peripheral arterial disease was unknown).
Discussion
In this pooled analysis of 671 adult patients with
moderate-to-severe RLS, previous exposure to DAs did
not significantly alter the efficacy and TEAE profile of
GEn (600 mg or 1200 mg) given once daily compared
with placebo. There were no significant differences in
the change in IRLS Rating Scale total score (looking at
change from baseline both at week 12 and by visit) or in
the investigator-rated CGI-I responder status between
the DA-naive and DA-exposed patients in any of the
treatment groups. Although these findings are prelimin-
ary, it is worth noting that the limitations of these ana-
lyses include the fact that information on prior DA
treatment duration and dose were not available nor was
the rate of augmentation rigorously assessed, particularly
because patients with symptom augmentation were ex-
cluded from the trial. Regardless of prior DA exposure,
both GEn doses significantly improved change from
baseline in IRLS Rating Scale total score and CGI-I re-
sponse compared with placebo. The TEAE profile was
similar between DA-naive and DA-exposed patients,
with somnolence and dizziness being the most com-
monly reported TEAEs. The TEAEs reported in this
study are consistent with those of the primary analyses
[10-12] and with the overall safety profile of GEn [9].
Although DAs are the most commonly prescribed
agents for the treatment of RLS [5,7], there is mounting
concern about AEs associated with treatment with DA,
particularly augmentation and impulse control disorders
[16]. Augmentation involves an increase in the duration
(earlier onset), anatomy, and intensity of RLS symptoms.
Further, the incidence and severity of augmentation
*P=.020 for DA-naive vs DA-exposed groups treated with placebo.
§P<.05, ‡P<.01, †P<.001 for GEn (600 mg or 1200 mg) vs placebo in DA-naive and DA-exposed groups.
Figure 2 IRLS Rating Scale total score changes from baseline by visit in DA-naive (A) and DA-exposed (B) patients. MMRM analysis.
Change from baseline reported as the LS mean change from baseline. Within the placebo group, there were no statistically significant differences
in change in IRLS Rating Scale total score from baseline between the DA-naive vs DA-exposed patients in any treatment arm at any of the visits,
except at week 1. Within the GEn 600-mg and GEn 1200-mg groups, there were no statistically significant differences in change in IRLS Rating
Scale total score from baseline between the DA-naive vs DA-exposed patients in any treatment arm at any of the visits. DA, dopamine agonist;
GEn, gabapentin enacarbil; IRLS, International Restless Legs Scale; LS, least squares; MMRM, mixed-effect model for repeated measures; W, week.
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usually resolves over weeks once DA treatment is dis-
continued [6]. This period, however, can be complicated
by severe RLS symptoms, which are not always resolved
by switching from one DA to another [17,18]. These are
important points to note when considering treatment
with DAs, as the dose and duration of prior DA expos-
ure are related to the likelihood of augmentation, and
augmentation is associated with a decrease in the re-



















































Placebo GEn 600 m
P <.001 for GEn (600 mg or 1200 mg) vs plac
P =.001 for GEn (600 mg or 1200 mg) vs plac
Figure 3 Percentage of responders on the investigator-rated CGI-I in
was defined as “much” or “very much” improved at week 12. CGI-I, Clinical
agonist; GEn, gabapentin enacarbil; OR, odds ratio.analysis found that DAs are also associated with impulse
control disorders including pathological gambling, com-
pulsive shopping, and hypersexuality [19]. These data
show the need for more prominent warnings for DAs as
part of their prescribing information.
To our knowledge, the effect of starting non-DA treat-
ments after a short washout period has not been studied
in adequately controlled clinical trials, although a case
report detailed that the alpha-2-delta ligand pregabalin




OR (95% CI): 
0.6 (0.3–1.2)
P=.133
g GEn 1200 mg
DA-exposed
DA-naive
ebo in the DA-naive group. 
ebo in the DA-exposed group.
DA-naive vs DA-exposed patients (week 12). Response on the CGI-I
Global Impression–Improvement; CI, confidence interval; DA, dopamine
Table 2 Most frequent TEAEs in ≥5% of the safety population of any treatment groupsa













Any event 149 (76) 105 (79) 187 (86) 34 (68) 27 (90) 40 (77)
Somnolence 12 (6) 25 (19) 54 (25) 0 7 (23) 7 (14)
Dizziness 9 (5) 20 (15) 44 (20) 2 (4) 2 (7) 15 (29)
Headache 22 (11) 12 (9) 36 (17) 5 (10) 7 (23) 4 (8)
Nasopharyngitis 10 (5) 13 (10) 17 (8) 6 (12) 1 (3) 4 (8)
Nausea 8 (4) 5 (4) 15 (7) 4 (8) 4 (13) 4 (8)
Fatigue 10 (5) 5 (4) 15 (7) 1 (2) 3 (10) 3 (6)
Diarrhea 10 (5) 3 (2) 7 (3) 2 (4) 3 (10) 3 (6)
Upper respiratory tract infection 7 (4) 6 (5) 5 (2) 2 (4) 3 (10) 1 (2)
Dry mouth 4 (2) 4 (3) 11 (5) 1 (2) 1 (3) 1 (2)
Constipation 6 (3) 0 7 (3) 2 (4) 3 (10) 3 (6)
Insomnia 6 (3) 7 (5) 4 (2) 1 (2) 1 (3) 2 (4)
Irritability 3 (2) 2 (2) 8 (4) 0 4 (13) 3 (6)
Back pain 6 (3) 4 (3) 6 (3) 1 (2) 2 (7) 1 (2)
Sinusitis 5 (3) 2 (2) 6 (3) 1 (2) 3 (10) 1 (2)
Increased weight 3 (2) 2 (2) 7 (3) 2 (4) 2 (7) 2 (4)
aAdditional AEs reported in ≥5% of the safety population (at an overall frequency lower than those shown in the table) were: flatulence, contusion, abnormal
coordination, toothache, increased appetite, urinary tract infection, depression, viral gastroenteritis, neck pain.
DA, dopamine agonist; GEn, gabapentin enacarbil; TEAE, treatment-emergent adverse events.
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guidelines, patients who experience augmentation due to
DAs may benefit from alternative treatments, including
alpha-2-delta ligands such as GEn [4], but no studies
have investigated this. Our analysis suggests that GEn
can be used to effectively treat RLS symptoms in pa-
tients with or without prior DA treatment, after a short
washout period.
RLS studies can also be complicated by a robust pla-
cebo response, and prior DA treatment status has been
shown to affect placebo response in patients with RLS
[21,22]. In a meta-analysis of double-blind, randomized,
placebo-controlled studies of patients with RLS, the pla-
cebo effect was particularly large for the primary out-
come measure (IRLS Rating Scale) but less so for scales
of daytime functioning [21]. Our analysis also found a
treatment difference in the change in IRLS Rating Scale
total score from baseline between DA-naive and DA-
exposed populations within the placebo group at week 1.
A blunted short-term placebo response resulting from
prior DA treatment could be a possible explanation for
these data.
Our analysis is limited to the data available from the
individual trials. In particular, data on prior DA expos-
ure is limited to the type of DA used, and the washout
period following DA treatment was ≥2 weeks. As noted
previously, information is not available to describethe duration, dosage, and other details of previous
dopaminergic treatment, leaving an important gap. As the
severity and duration of RLS symptoms were greater in
the DA-exposed group than in the DA-naive group, one
might expect the DA-exposed group to have less of a
response to GEn treatment; however, this was not the
case. Although DA treatment ended at least 2 weeks be-
fore study initiation, the exact washout period following
DA treatment was also unknown, raising the question of
potential additive effects of DA treatment in the DA-
exposed group. In addition to these limitations, the sample
size of the DA-naive group was considerably larger than
the DA-exposed group, and there were fewer patients with
severe RLS in the DA-naive group than in the DA-
exposed group, as one might expect. This was not a formal
meta-analysis; therefore, the scope of this pooled analysis
was limited to the GEn doses, treatment duration, and
patient populations assessed in the XP052, XP053, and
XP081 trials. Despite these limitations, the question
whether previous exposure to a DA affects the efficacy of
an alternate agent after changing treatment remains im-
portant clinically, and further studies that address these
limitations properly are necessary. In particular, it would
be worthwhile to examine prospectively whether earlier vs
more delayed treatment with a non-DA medication, such
as GEn, may lead to differential treatment effects in pa-
tients with RLS.
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In summary, limited, prior exposure to DA had no
significant effects on the efficacy or tolerability of GEn
(600 mg or 1200 mg) once daily in this pooled analysis
of adult patients with moderate-to-severe primary RLS.
These preliminary data might support the use of GEn in
non-augmented patients who were previously treated with
DA after a ≥2-week washout period, as well as in those
who are DA-naive.
Abbreviations
CGI-I: Clinical Global Impression–Improvement; DA: Dopamine agonist;
FDA: United States Food and Drug Administration; GEn: Gabapentin enacarbil;
IRLS: International Restless Legs Syndrome; mITT: Modified intent-to-treat;
MMRM: Mixed-effect model for repeated measures; RLS: Restless legs syndrome;
TEAE: Treatment-emergent adverse event.
Competing interests
WO served as a speaker for UCB Pharma, Lundbeck, Merz, and TEVA and
received grant support from US World Meds, UCB Pharma, and Ipsen. NH
served as a consultant for Allergan, Amgen, GlaxoSmithKline, Lundbeck, Teva,
UCB Pharma, and US Worldmeds, and received research support from Allergan,
Biotie, Chelsea Therapeutics, Merck, Pfizer, and Teva. DGB served as a consultant
for UCB, XenoPort Inc., Impax Pharmaceuticals, and Otsuka. MJ is a consultant to
XenoPort, Inc. RK and GS are employees of and own stock in XenoPort, Inc.
Authors’ contributions
WO participated in the interpretation of data and critical revision of the draft
for important intellectual content. NH participated in the interpretation of
data and critical revision of the draft for important intellectual content. DGB
participated in the interpretation of data and critical revision of the draft for
important intellectual content. MJ performed the analyses and helped to
draft the manuscript. RK participated in the analysis and interpretation of
data and critical revision of the draft for important intellectual content. GS
participated in the analysis and interpretation of data and helped draft the
manuscript. All authors have made substantial contributions to this work in
accordance with authorship criteria and have provided final approval of the
submitted version of this manuscript.
Acknowledgments
These studies and this analysis were conducted by XenoPort, Inc., Santa Clara,
CA. Medical writing support was provided by Sachi Yim and Meredith Kalish
from CodonMedical, a division of KnowledgePoint360 (an Ashfield Company),
and was funded by XenoPort, Inc.
Author details
1University of Texas Health Science Center at Houston, 6410 Fannin Street,
Suite 1010, Houston, TX 77030, USA. 2University of California Irvine
Movement Disorders Program, 100 Irvine Hall, Irvine, CA 92697, USA. 3Sleep
Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain. 4Summit
Analytical, LLC, 2422 Stout Street, Denver, CO 80205, USA. 5XenoPort, Inc.,
3410 Central Expressway, Santa Clara, CA 95051, USA.
Received: 21 November 2014 Accepted: 24 January 2015
References
1. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman
JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria:
updated International Restless Legs Syndrome Study Group (IRLSSG) consensus
criteria - history, rationale, description, and significance. Sleep Med.
2014;15:860–73.
2. Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B,
et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease:
evidence based guidelines and clinical consensus best practice guidance:
a report from the International Restless Legs Syndrome Study Group. Sleep
Med. 2013;14:675–84.3. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless
legs syndrome prevalence and impact: REST general population study. Arch
Intern Med. 2005;165:1286–92.
4. Garcia-Borreguero D, Stillman P, Benes H, Buschmann H, Chaudhuri KR,
Gonzalez Rodriguez VM, et al. Algorithms for the diagnosis and treatment of
restless legs syndrome in primary care. BMC Neurol. 2011;11:28.
5. Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome.
Neurotherapeutics. 2012;9:776–90.
6. Garcia-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W,
et al. Diagnostic standards for dopaminergic augmentation of restless legs
syndrome: report from a World Association of Sleep Medicine-International
Restless Legs Syndrome Study Group consensus conference at the Max
Planck Institute. Sleep Med. 2007;8:520–30.
7. Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless
legs syndrome with dopamine agonists. Arch Neurol. 2004;61:1393–7.
8. Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse
control disorders with the use of dopaminergic agents in restless legs
syndrome: a case–control study. Sleep. 2010;33:81–7.
9. HORIZANT® [package insert]. Santa Clara, CA: XenoPort Inc., 2013. Available at:
http://www.horizant.com/assets/docs/Horizant_PrescribingInformation.pdf.
10. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW, XP052
Study Group. Randomized, double-blind, placebo-controlled study of
XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72:439–46.
11. Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW, et al. A
randomized, double-blind, placebo-controlled study to assess the efficacy and
tolerability of gabapentin enacarbil in subjects with restless legs syndrome.
J Clin Sleep Med. 2011;7:282–92.
12. Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, et al. A randomized,
double-blind, placebo-controlled, dose–response study to assess the
pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects
with restless legs syndrome. Clin Neuropharmacol. 2012;35:165–73.
13. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J,
et al. Restless legs syndrome: diagnostic criteria, special considerations, and
epidemiology. A report from the restless legs syndrome diagnosis and
epidemiology workshop at the National Institutes of Health. Sleep Med.
2003;4:101–19.
14. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation
of the International Restless Legs Syndrome Study Group rating scale for
restless legs syndrome. Sleep Med. 2003;4:121–32.
15. Busner J, Targum SD. The clinical global impressions scale: applying a
research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.
16. Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al.
Restless legs syndrome (RLS) augmentation associated with dopamine agonist
and levodopa usage in a community sample. Sleep Med. 2011;12:431–9.
17. Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for
patient care. Drugs Aging. 2013;30:587–92.
18. García-Borreguero D, Allen RP, Benes H, Earley C, Happe S, Högl B, et al.
Augmentation as a treatment complication of restless legs syndrome:
concept and management. Mov Disord. 2007;22 suppl 18:S476–84.
19. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling,
hypersexuality, and compulsive shopping associated with dopamine
receptor agonist drugs. JAMA Intern Med. 2014;174:1930–3.
20. Silber MH. Sleep-related movement disorder. Continuum (Minneap Minn).
2013;19:170–84.
21. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the
placebo effect in restless legs syndrome treatment studies. Brain.
2008;131:902–17.
22. Ondo WG, Hossain MM, Gordon MF, Reess J. Predictors of placebo response
in restless legs syndrome studies. Neurology. 2013;81:193–4.
